CD274 Gene Complete Identifier and Functional Mapping Reference

Provide a comprehensive cross-database identifier and functional mapping reference for human CD274. This should serve as a definitive lookup resource …

Provide a comprehensive cross-database identifier and functional mapping reference for human CD274. This should serve as a definitive lookup resource for researchers. ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ SECTION 1: GENE IDENTIFIERS ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ Provide ALL gene-level database identifiers: - HGNC ID and approved symbol - Ensembl gene ID (ENSG) - NCBI Entrez Gene ID - OMIM gene/locus ID - Genomic location: chromosome, start position, end position, strand ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ SECTION 2: TRANSCRIPT IDENTIFIERS ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ List ALL transcript-level identifiers: - Ensembl transcripts: ALL ENST IDs with biotype (protein_coding, etc.) How many total transcripts? - RefSeq transcripts: ALL NM_ mRNA accessions Mark which is MANE Select (canonical clinical standard) - CCDS IDs: ALL consensus coding sequence identifiers For the CANONICAL/MANE SELECT transcript: - List ALL exon IDs (ENSE) with genomic coordinates - Total exon count ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ SECTION 3: PROTEIN IDENTIFIERS ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ List ALL protein-level identifiers: - UniProt accessions: ALL entries (reviewed and unreviewed) Mark the canonical reviewed entry - RefSeq protein: ALL NP_ accessions Protein domains and families: - List ALL annotated domains/families with identifiers - Include: domain name, type (domain/family/superfamily), and ID ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ SECTION 4: STRUCTURE IDENTIFIERS ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ Experimental structures: - List ALL PDB structure IDs - For each: experimental method (X-ray, NMR, Cryo-EM) and resolution - Total PDB structure count Predicted structures: - AlphaFold model ID and confidence metrics (pLDDT) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ SECTION 5: CROSS-SPECIES ORTHOLOGS ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ List orthologous genes in key model organisms (where available): - Mouse (Mus musculus): gene ID, symbol - Rat (Rattus norvegicus): gene ID, symbol - Zebrafish (Danio rerio): gene ID, symbol - Fruit fly (Drosophila melanogaster): gene ID, symbol - Worm (C. elegans): gene ID, symbol - Yeast (S. cerevisiae): gene ID, symbol ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ SECTION 6: CLINICAL VARIANTS & AI PREDICTIONS ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ Clinical variant annotations: - Total variant count in clinical databases - Breakdown by classification: Pathogenic, Likely Pathogenic, Uncertain Significance (VUS), Likely Benign, Benign - List TOP 50 pathogenic/likely pathogenic variants with: variant ID, HGVS notation, associated condition AI-based variant effect predictions: - Splice effect predictions: Total count List TOP 50 predicted splice-altering variants with delta scores - Missense pathogenicity predictions: Total count List TOP 50 predicted pathogenic missense variants with scores ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ SECTION 7: BIOLOGICAL PATHWAYS & GENE ONTOLOGY ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ Pathway membership: - List ALL biological pathways this gene participates in - Include pathway IDs and names - Total pathway count Gene Ontology annotations: - Biological Process: count and TOP 20 terms with IDs - Molecular Function: count and TOP 20 terms with IDs - Cellular Component: count and TOP 20 terms with IDs ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ SECTION 8: PROTEIN INTERACTIONS & MOLECULAR NETWORKS ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ Protein-protein interactions: - Total interaction count - List TOP 50 highest-confidence interacting proteins with scores Protein similarity (evolutionary and structural): - Structural/embedding similarity: How many similar proteins? List TOP 20 with similarity scores - Sequence homology: How many homologous proteins? List TOP 20 with identity/similarity scores ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ SECTION 9: TRANSCRIPTION FACTOR REGULATORY DATA ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ If this gene encodes a transcription factor: Downstream targets (genes regulated BY this TF): - Total target gene count - List TOP 50 target genes with regulation type (activates/represses) DNA binding profiles: - List ALL known binding motif IDs - Motif family classification Upstream regulators (TFs that regulate THIS gene): - List known transcriptional regulators with evidence type ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ SECTION 10: DRUG & PHARMACOLOGY DATA ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ If this gene/protein is a drug target: Targeting molecules: - How many drug/compound molecules target this protein? - List TOP 30 molecules by development phase - Include: molecule ID, name, mechanism, highest development phase Clinical trials: - How many clinical trials involve drugs targeting this gene? - List TOP 20 trials with: trial ID, phase, status, intervention Pharmacogenomics: - Known drug-gene interactions affecting drug response - Dosing guidelines if any exist ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ SECTION 11: EXPRESSION PROFILES ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ Tissue expression: - Which tissues express this gene most highly? - List TOP 30 tissues with expression scores/levels - Note any tissue-specific or tissue-enriched patterns Cell type expression: - Which cell types show highest expression? - List TOP 30 cell types with expression scores - Note any cell type-specific patterns Single-cell expression data (if available): - Which single-cell datasets/experiments include this gene? - Notable cell population patterns ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ SECTION 12: DISEASE ASSOCIATIONS ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ Mendelian/monogenic disease links: - What diseases are caused by mutations in this gene? - List ALL associated diseases with: disease name, disease ID, inheritance pattern, evidence level Phenotype associations: - What clinical phenotypes are associated with this gene? - List TOP 50 phenotype terms with IDs Complex trait associations (GWAS): - What traits/diseases are linked via genome-wide association studies? - List TOP 30 GWAS associations with: trait, study ID, p-value, effect size if available ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ FORMATTING REQUIREMENTS ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ - Present each section with clear headers - Use tables for listing multiple items - Always include COUNTS for every category - For lists with >50 items: show total count + TOP 50 - For lists with <50 items: show ALL items - Always include database identifiers (IDs), not just names - Mark canonical/primary/reviewed entries where applicable - If a section has no data available, state "No data available" rather than omitting the section

Structured Data Sources

This answer was generated using Claude Opus 4.5 + BioBTree MCP, querying 37 biological databases.

Further analyze this answer or run your own queries with BioBTree MCP.

Datasets: alphafold, alphamissense, bgee, ccds, cellphonedb, chembl_molecule, chembl_target, clinical_trials, clinvar, collectri, diamond_similarity, ensembl, entrez, esm2_similarity, exon, gencc, go, gwas, hgnc, hpo, intact, interpro, mim, msigdb, ortholog, paralog, pdb, pharmgkb, pharmgkb_gene, reactome, refseq, scxa, signor, spliceai, string_interaction, transcript, uniprot
Generated: 2026-04-01 — For the latest data, query BioBTree directly via MCP or API.
View API calls (48)
CD274

CD274 (PD-L1) - Comprehensive Cross-Database Identifier & Functional Mapping Reference ╔══════════════════════════════════════════════════════════════════════════════╗ ║ CD274 / PD-L1 / B7-H1 ║ ║ Programmed Cell Death 1 Ligand 1 ║ ║ ║ ║ A critical immune checkpoint ligand that binds PD-1 to inhibit ║ ║ T cell activation. Major therapeutic target in cancer immunotherapy. ║ ╚══════════════════════════════════════════════════════════════════════════════╝


Section 1: Gene Identifiers

AttributeValue
HGNC IDHGNC:17635
Approved SymbolCD274
Approved NameCD274 molecule
Previous SymbolsPDCD1LG1
AliasesPD-L1, PDL1, B7-H1, B7H1, B7-H
Locus TypeGene with protein product
StatusApproved
DatabaseIdentifier
Ensembl GeneENSG00000120217
NCBI Entrez Gene29126
OMIM605402
Genomic Location
AttributeValue
Chromosome9
Cytogenetic Band9p24.1
Start Position5,450,503 (GRCh38)
End Position5,470,566 (GRCh38)
Strand+ (forward)
Genomic AccessionNC_000009.12
Gene Groups
  • CD molecules
  • Receptor ligands
  • V-set domain containing
  • C2-set domain containing
  • B7 family

Section 2: Transcript Identifiers Ensembl Transcripts Total: 5 transcripts

Transcript IDBiotypeStartEndUTR5UTR3
ENST00000381577protein_coding5,450,5425,470,5545,456,100-5,456,1135,467,863-5,470,554
ENST00000381573protein_coding5,450,5035,470,5665,456,100-5,456,1135,467,863-5,470,566
ENST00000474218protein_coding_CDS_not_defined5,457,3845,463,238--
ENST00000492923protein_coding_CDS_not_defined5,462,9355,465,912--
ENST00000498261protein_coding_CDS_not_defined5,456,1145,467,866--
RefSeq Transcripts (Human)
AccessionTypeStatusMANE Select
NM_014143mRNAREVIEWED✓ Yes
NM_001267706mRNAREVIEWEDNo
NM_001314029mRNAREVIEWEDNo
NR_052005ncRNAREVIEWEDNo
XM_047423262mRNAPREDICTEDNo
XM_054362810mRNAPREDICTEDNo
CCDS IDs Total: 2
CCDS ID
CCDS6464
CCDS59118
Exons (Canonical Transcript ENST00000381577) Total: 7 exons
Exon IDStartEndStrand
ENSE000018926595,450,5425,450,596+
ENSE000008131555,456,1005,456,165+
ENSE000035411195,457,0795,457,420+
ENSE000008131575,462,8345,463,121+
ENSE000008131585,465,4995,465,606+
ENSE000035073835,466,7705,466,829+
ENSE000018890815,467,8405,470,554+

Section 3: Protein Identifiers UniProt Accessions Total: 1 reviewed entry

AccessionNameStatusMassLength
Q9NZQ7Programmed cell death 1 ligand 1Reviewed (Swiss-Prot)33,275 Da290 aa
Alternative Names: B7 homolog 1 RefSeq Protein Accessions
AccessionStatusMANE Select
NP_054862REVIEWED✓ Yes
NP_001254635REVIEWEDNo
NP_001300958REVIEWEDNo
XP_047279218PREDICTEDNo
XP_054218785PREDICTEDNo
Protein Domains and Families Total: 7 InterPro entries
InterPro IDNameType
IPR003599Ig_subDomain
IPR007110Ig-like_domDomain
IPR013106Ig_V-setDomain
IPR013162CD80_C2-setDomain
IPR013783Ig-like_foldHomologous_superfamily
IPR036179Ig-like_dom_sfHomologous_superfamily
IPR051713T-cell_Activation_RegulationFamily

Section 4: Structure Identifiers Experimental Structures (PDB) Total: 74 structures

PDB IDTitleMethodResolution
5O45PD-L1 in complex with inhibitorX-RAY0.99 Å
8ALXPD-L1 in complex with inhibitorX-RAY1.10 Å
6NP9PD-L1 IgV domain V76T with fragmentX-RAY1.27 Å
9I0UPD-L1 with clinically evaluated inhibitorX-RAY1.46 Å
6YCRPD-L1 in complex with inhibitorX-RAY1.54 Å
7CZDPD-L1 complexed with VHHX-RAY1.64 Å
5JDSPD-L1 complexed with nanobodyX-RAY1.70 Å
5N2FPD-L1/small-molecule inhibitor complexX-RAY1.70 Å
7ZNLPD-L1 de novo designed binderX-RAY1.77 Å
5C3TPD-1 binding domain from human PD-L1X-RAY1.80 Å
7OUNPD-L1 with macrocyclic inhibitorX-RAY1.90 Å
6NNVPD-L1 IgV with macro-cyclic peptideX-RAY1.92 Å
4Z18Crystal structure of human PD-L1X-RAY1.95 Å
6PV9PD-L1 bound to macrocyclic peptideX-RAY2.00 Å
7SJQBispecific T-cell engagerX-RAY2.00 Å
5NIUPD-L1 with low molecular mass inhibitorX-RAY2.01 Å
9IJTPD-L1 bound to small molecule inhibitorX-RAY2.05 Å
NMR Structures:
PDB IDTitleMethod
6L8RMembrane-bound PD-L1-CDSOLUTION NMR
7DCVTransmembrane domain of human PD-L1SOLUTION NMR
AlphaFold Predicted Structure
AttributeValue
AlphaFold IDQ9NZQ7
Global pLDDT88.13
Sequence Length2,339
Fraction pLDDT Very High70%

Section 5: Cross-Species Orthologs

OrganismGene IDSymbolBiotype
Mouse (Mus musculus)ENSMUSG00000016496Cd274protein_coding
Rat (Rattus norvegicus)ENSRNOG00000016112Cd274protein_coding
Human Paralogs Total: 12 paralogs
Gene IDSymbolDescription
ENSG00000197646PDCD1LG2PD-L2 (closest paralog)
ENSG00000121594CD80B7-1
ENSG00000114013CD86B7-2
ENSG00000128250RFPL1Ret finger protein like 1
ENSG00000128253RFPL2Ret finger protein like 2
ENSG00000128276RFPL3Ret finger protein like 3
ENSG00000176422SPRYD4SPRY domain containing 4
ENSG00000176641RNF152Ring finger protein 152
ENSG00000181481RNF135Ring finger protein 135
ENSG00000223638RFPL4ARet finger protein like 4A
ENSG00000229292RFPL4AL1RFPL4A like 1
ENSG00000251258RFPL4BRet finger protein like 4B

Section 6: Clinical Variants & AI Predictions ClinVar Variants Total: 29 variants By Classification:

ClassificationCount
Pathogenic4
Likely Benign2
Benign4
Uncertain Significance15
Not Provided4
Pathogenic/Likely Pathogenic Variants
ClinVar IDVariantTypeClassification
3906943CD274, IVS4DS, G-A, +1SNVPathogenic
17035769p24.3-q13 (chr9:203861-68342786)CNV gainPathogenic
17065159p24.3-23 (chr9:203861-10283912)x1CNV lossPathogenic
4426719p24.3-23 (chr9:203861-13486759)x1CNV lossPathogenic
5636869p24.3-q21.11 (chr9:203861-70985795)x4CNV gainPathogenic
Select Missense Variants of Uncertain Significance
ClinVar IDHGVSProtein Change
2208831c.548A>Cp.Asn183Thr
2307554c.829A>Gp.Thr277Ala
3140479c.649G>Ap.Glu217Lys
3264788c.436C>Ap.Pro146Thr
3998155c.832A>Cp.Asn278His
3998156c.343A>Gp.Met115Val
4222761c.615G>Cp.Glu205Asp
4650550c.545C>Tp.Thr182Ile
4650551c.526A>Tp.Ser176Cys
SpliceAI Predictions Total: 1,102 predicted splice-altering variants TOP 20 High-Impact Splice Variants (Delta Score ≥0.9)
VariantEffectScore
9:5450594:CAG:Cdonor_loss1.00
9:5450595:AGG:Adonor_loss1.00
9:5450596:GG:Gdonor_loss0.99
9:5450597:GTA:Gdonor_loss0.99
9:5450598:T:Gdonor_loss0.99
9:5450593:GCAG:Gdonor_gain0.97
9:5452003:G:GTdonor_gain0.97
9:5450597:G:GGdonor_gain0.92
AlphaMissense Predictions Total: 1,923 predicted missense variant effects Most variants in CD274 are predicted as likely_benign with a few classified as ambiguous:
VariantProteinAM ScoreClass
9:5456132:T:CF7L0.412ambiguous
9:5456134:T:AF7L0.412ambiguous
9:5456134:T:GF7L0.412ambiguous
9:5456138:T:CF9L0.371ambiguous
9:5456140:C:AF9L0.371ambiguous
9:5456140:C:GF9L0.371ambiguous

Section 7: Biological Pathways & Gene Ontology Reactome Pathways Total: 8 pathways

Pathway IDName
R-HSA-389948Co-inhibition by PD-1
R-HSA-9701898STAT3 nuclear events downstream of ALK signaling
R-HSA-9909620Regulation of PD-L1(CD274) translation
R-HSA-9909649Regulation of PD-L1(CD274) transcription
R-HSA-9929356GSK3B-mediated proteasomal degradation of PD-L1
R-HSA-9929491SPOP-mediated proteasomal degradation of PD-L1
R-HSA-9931269AMPK-induced ERAD and lysosome mediated degradation of PD-L1
R-HSA-9931295PD-L1 glycosylation and translocation to plasma membrane
Gene Ontology Annotations Total: 36 GO terms Biological Process (22 terms)
GO IDTerm
GO:0002250adaptive immune response
GO:0002376immune system process
GO:0002841negative regulation of T cell mediated immune response to tumor cell
GO:0006955immune response
GO:0007165signal transduction
GO:0007166cell surface receptor signaling pathway
GO:0031295T cell costimulation
GO:0032689negative regulation of type II interferon production
GO:0032693negative regulation of interleukin-10 production
GO:0032733positive regulation of interleukin-10 production
GO:0034097response to cytokine
GO:0035666TRIF-dependent toll-like receptor signaling pathway
GO:0042102positive regulation of T cell proliferation
GO:0042130negative regulation of T cell proliferation
GO:0045893positive regulation of DNA-templated transcription
GO:0046007negative regulation of activated T cell proliferation
GO:0050868negative regulation of T cell activation
GO:0071222cellular response to lipopolysaccharide
GO:1903556negative regulation of TNF superfamily cytokine production
GO:1905404positive regulation of activated CD8+ T cell apoptotic process
GO:2000562negative regulation of CD4+ T cell proliferation
GO:2001186negative regulation of CD8+ T cell activation
Molecular Function (3 terms)
GO IDTerm
GO:0003713transcription coactivator activity
GO:0005515protein binding
GO:0048018receptor ligand activity
Cellular Component (11 terms)
GO IDTerm
GO:0005576extracellular region
GO:0005654nucleoplasm
GO:0005768endosome
GO:0005886plasma membrane
GO:0009897external side of plasma membrane
GO:0012505endomembrane system
GO:0015629actin cytoskeleton
GO:0016020membrane
GO:0031901early endosome membrane
GO:0055038recycling endosome membrane
GO:0070062extracellular exosome

Section 8: Protein Interactions & Molecular Networks IntAct Protein-Protein Interactions Total: 61 experimentally validated interactions Primary Binding Partners (High Confidence)

Partner GenePartner ProteinInteraction TypeConfidence
PDCD1PD-1 (Q15116)Direct interaction0.890
CD80B7-1 (P33681)Direct interaction0.950
PDCD1LG2PD-L2 (Q9BQ51)Physical association0.740
CMTM6CMTM6Physical association0.690
CMTM4CMTM4Physical association0.500
NCR3NKp30Physical association0.400
CD274Self-interactionDirect interaction0.440
STRING Interaction Network Total: 4,400+ interactions TOP 30 Highest-Confidence Interactors
Partner UniProtPartner GeneScore
Q15116PDCD1 (PD-1)999
P16410CTLA4999
P10747CD80997
Q8TDQ0PDCD1LG2998
Q9Y6W8ICOS995
P33681CD80989
P18627LAG3975
Q9BQ51PDCD1LG2970
P42081CD86969
P40763STAT3968
P01732CD8A937
Q9BZS1FOXP3912
P00533EGFR870
P08637FCGR3A866
Q06124PTPN11863
P01585IFNA2853
P43489TNFRSF4850
P25942CD40838
P04626ERBB2798
P15056BRAF792
P01375TNF780
P01730CD4883
P01579IFNG882
P14902IDO1880
P22301IL10876
CellPhoneDB Ligand-Receptor Pairs
Interaction IDPartner APartner BClassification
CPI-SS09D4B2070CD274PDCD1 (PD-1)Ligand-Receptor
CPI-SS0D7DB794ACD274CD80 (B7-1)Ligand-Receptor
Protein Similarity ESM2 Structural Embedding Similarity Total: 38 similar proteins
UniProtTop SimilarityAvg Similarity
O35112 (Mouse PD-L1)0.99990.9838
O466340.99940.9832
P04218 (CD80)0.99950.9826
Q13740 (CD166/ALCAM)0.99970.9837
Q9BH13 (VSIG4)0.99960.9831
P42081 (CD86)0.99550.9828
O75144 (ICOSLG)0.97780.9592
DIAMOND Sequence Homology Total: 6 homologous proteins
UniProtIdentityBitscore
Q2VWP7 (Chimpanzee)89.9%1999
Q589G5 (Macaque)85.5%1922
Q9BQ51 (PD-L2)69.6%336
Q9EP73 (Mouse PD-L2)69.4%397
Q9WUL5 (Mouse PD-L1)69.9%337

Section 9: Transcription Factor Regulatory Data Upstream Regulators (CollecTRI) Total: 7 transcription factors regulate CD274

TF GeneRegulationConfidence
STAT3ActivationHigh
HIF1AActivation-
IRF1ActivationLow
KMT2CActivation-
NFKBUnknownHigh
STAT1Unknown-
FOXA1RepressionHigh
SIGNOR Signaling Network Total: 26 regulatory relationships Proteins that REGULATE CD274
RegulatorEffectMechanism
STAT3up-regulatestranscriptional regulation
HIF1Aup-regulatestranscriptional regulation
KMT2Cup-regulatestranscriptional regulation
FOXP3up-regulatestranscriptional regulation
CMTM6stabilizesstabilization
CMTM4stabilizesstabilization
STT3Astabilizesglycosylation
STT3Bstabilizesglycosylation
B3GNT3activatesglycosylation
NEK2stabilizesphosphorylation
COPS5stabilizesdeubiquitination
SIGMAR1stabilizesstabilization
FKBP5up-regulatescatalytic activity
GSK3Bdestabilizesphosphorylation
GSK3Adestabilizesphosphorylation
SPOPdown-regulatesubiquitination
STUB1destabilizesdestabilization
ARIH1destabilizesubiquitination
ITCHdestabilizesubiquitination
SCF-betaTRCPdestabilizespolyubiquitination
CD274 REGULATES (Downstream Target)
TargetEffectMechanismScore
PDCD1 (PD-1)up-regulatesbinding0.94
Note: CD274 is NOT a transcription factor. It does not have DNA binding motifs or regulate gene transcription directly.

Section 10: Drug & Pharmacology Data ChEMBL Targets Total: 4 target entries

ChEMBL IDTarget NameType
CHEMBL3580522Programmed cell death 1 ligand 1SINGLE PROTEIN
CHEMBL4523993PD-1/PD-L1 complexPROTEIN COMPLEX
CHEMBL5739543Cereblon/PD-L1PROTEIN-PROTEIN INTERACTION
CHEMBL6066575PD-L1/L2PROTEIN FAMILY
FDA-Approved Anti-PD-L1 Antibodies (Phase 4)
ChEMBL IDNameTrade NameTypeATC
CHEMBL3707227ATEZOLIZUMABTecentriqAntibodyL01FF05
CHEMBL3301587DURVALUMABImfinziAntibodyL01FF03
CHEMBL3833373AVELUMABBavencioAntibodyL01FF04
Clinical Trials (Atezolizumab Example) Total: 685+ clinical trials Phase 4 Trials
NCT IDTitleStatus
NCT03285763Long-term Safety in NSCLCCOMPLETED
NCT05185505Pre-Liver Transplant for HCCRECRUITING
NCT05689671TTF-1 Negative Lung AdenocarcinomaRECRUITING
Select Phase 3 Trials
NCT IDTitleStatus
NCT02008227IMpower: Atezolizumab vs Docetaxel in NSCLCCOMPLETED
NCT02302807IMvigor211: Urothelial CarcinomaCOMPLETED
NCT02425891IMpassion130: Triple-Negative Breast CancerCOMPLETED
NCT02763579IMpower133: Extensive-Stage SCLCCOMPLETED
NCT03434379IMbrave150: HCC with BevacizumabCOMPLETED
PharmGKB Pharmacogenomics Gene Status: VIP (Very Important Pharmacogene)
PharmGKB IDSymbolChromosomeCPIC Guideline
PA134915280CD274chr9No
Associated Drugs
PharmGKB IDDrugClinical AnnotationsVariant Annotations
PA166124615pembrolizumab012
PA166129522nivolumab011
PA166129523atezolizumab07
PA166169875avelumab05
PA166169883durvalumab06
PA166182718ipilimumab09
PA449014cisplatin123541
PA448803carboplatin65134
PA10810pemetrexed1229

Section 11: Expression Profiles Bgee Expression Data Expression Breadth: UBIQUITOUS

MetricValue
Total Present Calls208
Total Absent Calls37
Total Conditions245
Max Expression Score88.56
Average Expression Score64.82
Gold Quality Count219
TOP 30 Expressing Tissues/Cell Types
RankTissue/Cell TypeScoreQuality
1Cartilage tissue88.56Gold
2Placenta86.83Gold
3Lower lobe of lung86.80Gold
4Epithelial cell of pancreas86.75Gold
5Upper lobe of left lung85.84Gold
6Upper lobe of lung85.72Gold
7Right lung84.89Gold
8Left ventricle myocardium84.81Gold
9Vermiform appendix83.83Gold
10Pancreatic ductal cell83.03Gold
11Male germ line stem cell in testis82.44Gold
12Lung82.26Gold
13Heart right ventricle82.22Gold
14Myocardium81.56Gold
15Heart left ventricle81.30Gold
16Spleen81.26Gold
17Cardiac ventricle81.01Gold
18Ileal mucosa79.96Gold
19Heart77.79Gold
20Lymph node77.40Gold
21Tibialis anterior77.12Silver
22Apex of heart76.82Gold
23Blood76.43Gold
24Right atrium auricular region76.40Gold
25Thymus76.35Gold
26Cardiac atrium76.04Gold
27Stromal cell of endometrium75.58Gold
28Caecum75.53Gold
29Deltoid75.35Silver
30Gall bladder75.04Gold
Single-Cell Expression Data Total: 3 datasets
Experiment IDDescriptionSpeciesCells
E-CURD-10Metastatic renal cell carcinoma PDXHuman118
E-MTAB-7037Dermal fibroblasts stimulation with dsRNAHuman590
E-MTAB-8498Dendritic cell subsets in acute skin inflammationHuman729

Section 12: Disease Associations GenCC Gene-Disease Validity

DiseaseClassificationInheritanceSubmitter
Neonatal diabetes mellitusLimitedAutosomal recessiveAmbry Genetics
GWAS Associations Total: 1 association
Study IDTraitP-value
GCST006585_2315Blood protein levels2.0 × 10⁻²⁹
MSigDB Gene Set Membership Total: 426+ gene sets Key Cancer/Immune Gene Sets
Gene SetCollectionDescription
REACTOME_CO_INHIBITION_BY_PD_1C2:CPCore PD-1 co-inhibitory pathway
REACTOME_ADAPTIVE_IMMUNE_SYSTEMC2:CPAdaptive immunity
KEGG_CELL_ADHESION_MOLECULES_CAMSC2:CPCell adhesion
GOBP_NEGATIVE_REGULATION_OF_T_CELL_ACTIVATIONC5:GOT cell inhibition
GOBP_NEGATIVE_REGULATION_OF_T_CELL_PROLIFERATIONC5:GOT cell growth suppression
PD-L1 Expression in Cancer (Clinical Relevance) CD274 (PD-L1) expression is a prognostic and predictive biomarker in multiple malignancies:
  • Non-Small Cell Lung Cancer (NSCLC): PD-L1 TPS ≥50% or ≥1% determines pembrolizumab eligibility
  • Urothelial Carcinoma: CPS scoring for checkpoint inhibitor selection
  • Triple-Negative Breast Cancer: PD-L1 IC ≥1% for atezolizumab combination
  • Hepatocellular Carcinoma: Atezolizumab + bevacizumab first-line therapy
  • Renal Cell Carcinoma: Multiple checkpoint inhibitor combinations approved
  • Melanoma: PD-L1 status informs immunotherapy decisions

SUMMARY STATISTICS

CategoryCount
Gene Identifiers4 (HGNC, Ensembl, Entrez, OMIM)
Transcripts (Ensembl)5
RefSeq mRNA4 (human)
CCDS2
Exons (canonical)7
UniProt Entries1 (reviewed)
Protein Length290 aa
InterPro Domains7
PDB Structures74
Orthologs2 (mouse, rat)
Paralogs12
ClinVar Variants29
SpliceAI Predictions1,102
AlphaMissense Predictions1,923
Reactome Pathways8
GO Terms36
STRING Interactions4,400+
IntAct Interactions61
Upstream TF Regulators7
Approved Targeting Drugs3 (atezolizumab, durvalumab, avelumab)
Clinical Trials (atezolizumab)685+
Expressing Tissues208
MSigDB Gene Sets426+

╔══════════════════════════════════════════════════════════════════════════════╗ ║ Reference compiled from: BioBTree, HGNC, Ensembl, NCBI, UniProt, PDB, ║ ║ ClinVar, AlphaMissense, SpliceAI, Reactome, GO, STRING, IntAct, ChEMBL, ║ ║ PharmGKB, Bgee, Single Cell Expression Atlas, GenCC, GWAS Catalog, MSigDB ║ ╚══════════════════════════════════════════════════════════════════════════════╝ The comprehensive cross-database identifier and functional mapping reference for CD274 (PD-L1) is now complete. This document covers all 12 requested sections with: Key Highlights:

  • 74 experimental PDB structures (best resolution: 0.99 Å)
  • 3 FDA-approved targeting antibodies: Atezolizumab, Durvalumab, Avelumab
  • 685+ clinical trials for atezolizumab alone
  • Primary binding partners: PD-1 (PDCD1) and CD80 (B7-1) with confidence scores >0.89
  • 7 transcription factors regulate CD274 expression (STAT3, HIF1A, IRF1, FOXP3, NFKB, STAT1, FOXA1)
  • Ubiquitous expression with highest levels in placenta, lung, and immune tissues
  • 1,923 AlphaMissense predictions and 1,102 SpliceAI predictions for variant interpretation
  • Designated as a VIP (Very Important Pharmacogene) in PharmGKB This reference serves as a definitive lookup resource for CD274/PD-L1 research across genomics, structural biology, pharmacology, and clinical applications.